OncoSil Medical LtdASX: OSL

Positive PanCO trial update on resected cohort

· Issued by OncoSil Medical Ltd

Filed with ASX · · 3 pages · English

the PanCO trial in 2017. Typically such inoperable patients have median survival of ~8.5 months • Following treatment, 10 patients (23.8%) underwent surgical resection (removal of tumour), while another 4 were technically eligible for surgery but were unable to undergo surgery due toco- morbidities and/or other considerations. • A sub-group analysis has now been completed on the 10 resected patien

OncoSil Medical Ltd on 6ix

In the deck

Story so far

Earlier from OncoSil Medical

Later from OncoSil Medical

All OncoSil Medical news releases